Name: Ipamoreln + CJC-1295 No DAC Blend Research Peptide | Peptide Minds
Price: 65.00 USD
Availability: InStock

Description

⚠️ LABORATORY RESEARCH USE ONLY — NOT FOR HUMAN OR ANIMAL CONSUMPTION
This product is supplied exclusively for in vitro and laboratory research by qualified personnel. It is not approved by the FDA for any clinical, therapeutic, diagnostic, cosmetic, dietary, or veterinary application.

Ipamoreln + CJC-1295 No DAC Blend (5 mg / 5 mg)

This research kit co-packages two well-characterized synthetic peptides that act on complementary receptors of the GH-secretory axis: Ipamoreln, a selective GHS-R1a (ghrelin receptor) agonist, and CJC-1295 No DAC (Mod GRF 1-29), a stabilized 29-residue GHRH analog. Co-packaging allows laboratories to study receptor cross-talk and synergistic signaling within a single experimental framework. Each peptide is supplied as a lyophilized powder, 5 mg.

Product Specifications

Product Name	Ipamoreln + CJC-1295 No DAC Blend
Component 1	Ipamoreln — CAS 170851-70-4; C₃₈H₄₉N₉O₅; ≈711.9 g/mol; Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Component 2	CJC-1295 No DAC (Mod GRF 1-29) — CAS 863288-34-0; C₁₅₂H₂₅₂N₄₄O₄₂; ≈3,368 g/mol
Quantity	5 mg + 5 mg (separate vials)
Form	Lyophilized powder
Purity	≥98% (HPLC); see third-party COA
Classification	Synthetic peptides — GHS-R1a / GHRH-R research reagents

Mechanistic Background

Ipamoreln engages the ghrelin receptor while CJC-1295 No DAC engages the GHRH receptor; the two pathways converge on somatotroph cAMP and calcium signaling, which is why the pair is a standard model for studying additive and synergistic secretagogue effects in laboratory systems.

Research Applications

The two compounds are studied individually and in combination in in vitro receptor assays and preclinical model systems to investigate:

GHS-R1a and GHRH-receptor co-activation and downstream cAMP / calcium signaling
Pituitary somatotroph cell-culture models of pulsatile GH release
Receptor cross-talk and synergy between secretagogue and GHRH-analog pathways
Selectivity comparisons against earlier GHRP-class ligands
GH/IGF-1 axis signaling in endocrinology models
Peptide stability and analytical method development for the modified GHRH sequence

Storage & Handling

Store lyophilized material at −20 °C, protected from light and moisture. Allow the vial to reach room temperature before opening. Following reconstitution in a suitable laboratory buffer, store at 2–8 °C and use within the timeframe established by your laboratory’s stability protocols. Avoid repeated freeze–thaw cycles. Handle in accordance with standard laboratory practice for peptide reagents.

Published Literature

Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561.
Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805.

Research Use Only Statement

Ipamoreln + CJC-1295 No DAC Blend (5 mg / 5 mg) is a chemical reagent supplied solely for laboratory research and analytical purposes. It is not a drug, dietary supplement, cosmetic, food additive, or medical device, and it has not been evaluated by the U.S. Food and Drug Administration. It is not intended to diagnose, treat, cure, or prevent any disease in humans or animals. Peptide Minds is a research chemical supplier and is not a pharmacy, compounding facility, or medical provider. The purchaser is responsible for ensuring the material is handled by trained personnel in accordance with all applicable laws, regulations, and institutional policies.